Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis (TCIM-ELAII)

Clinical Trial in Phase II of Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis.

Our working hypothesis is that the injection of autologous bone marrow mononuclear cells (BMNC) has a positive effect on the natural loss of motor units and on the increase in the size of the motor unit that occurs in patients with ALS during the evolution of the disease

Study Overview

• Status: Not yet recruiting
• Conditions: ALS (Amyotrophic Lateral Sclerosis)
• Intervention / Treatment: Drug: MNC (Mononuclear cells); Drug: Placebo / Saline

Detailed Description

Our working hypothesis is that the injection of autologous bone marrow mononuclear cells (BMNC) has a positive effect on the natural loss of motor units and on the increase in the size of the motor unit that occurs in patients with ALS during the evolution of the disease.

This hypothesis is based on experimental work done in animal models of ALS and the results of our previous phase I clinical trial. In this clinical trial (TCIM / ALS, ClinicalTrials.gov Identifier: NCT02286011) we studied with electrophysiological techniques (in a small number of patients with ALS) the effects of intramuscular injection of a single dose of BMSC in the tibialis anterioris (TA) muscle. . The results indicate that this is a safe procedure and show the presence of a positive and apparently transitory effect on the size and number of motor units of the TA muscle.

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Miguel Blanquer Blanquer, MD; Phone Number: 968 36 95 00; Email: miguelblanquer@um.es

Study Locations

• Spain
  • Murcia, Spain, 30003
    • Hospital Clínico Universitario Virgen de la Arrixaca
    • Contact: Miguel Blanquer Blanquer; Phone Number: 968359767
    • Principal Investigator: Miguel Blanquer Blanquer, MD
    • Principal Investigator: Carmen Díaz Marín, MD
    • Principal Investigator: Teresa Gavilá Lattur, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of ALS defined or probable according to the criteria established by the World Federation of Neurology
• Age between 18 and 70 years.
• Patient who offers sufficient guarantees of adherence to the protocol.
• Neurophysiological data confirming lower motor neuron involvement at the lumbar and cervical level.
• Assessment of the motor deficit in the dorsal flexion of both feet (between 3 and 5 points on the MRC scale).

Exclusion Criteria:

• Mellitus diabetes.
• Other diseases that may be associated with polyneuropathies.
• Previous history of cerebral stroke.
• Previous pathology of the peripheral nervous system that affected one or both lower or upper limbs, with or without clinically evident neurological sequelae.
• Pregnant or actively breastfeeding patients
• Patients physiologically capable of becoming pregnant, unless they are using a reliable contraceptive method (Annex III)
• Patients with cardiac, renal, hepatic, systemic, immune disease that may influence the survival of the patient during the test.
• Positive serology for hepatitis B, hepatitis C or HIV.
• Clinical and anesthesiological criteria that contraindicate either sedation or the extraction of BM itself (Alteration of the coagulation system or anticoagulated patient with inability to withdraw anticoagulation, hemodynamic instability, skin alteration in the puncture site, etc.)
• Inclusion in other clinical trials in the last 6 months.
• Inability to understand informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MNC (Mononuclear cells); MNC (Mononuclear cells) (patients in which stem cells will be injected into the two muscles on one side and placebo -vehicle- in the two contralateral muscles). This group would consist of 74 patients.	Drug: MNC (Mononuclear cells); Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side); Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side); Drug: Placebo / Saline; - Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
Placebo Comparator: Saline; (patients in which placebo -vehicle- will be injected into both muscles on both sides). This group would consist of 26 patients.	Drug: Placebo / Saline; - Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of serious and non-serious adverse events related to the use of bone marrow mononuclear cells in patients with Amyotrophic Lateral Sclerosis		48 months from baseline
D50 index obtained from stimulus intensity curves	This parameter quantifies the number and size of the functional motor units of a given muscle.	48 months from baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Motor unit number index" (MUNIX)	The unit amplitude (or area) of the individual motor units are calculated from the amplitude variations (or area) of the muscle action potential obtained in response to stimuli from a fixed intensity	48 months from baseline
Motor unit size index" (MUSIX)	The unit amplitude (or area) of the individual motor units are calculated from the amplitude variations (or area) of the muscle action potential obtained in response to stimuli from a fixed intensity	48 months from baseline
Fiber density (FD)	Quantifies the average number of muscle fibers per motor unit. It is obtained from single fiber recordings made with electrodes. The average number of motor unit potentials is calculated in 20 different positions in the muscle.	48 months from baseline
PAMC amplitude: mV	Compound muscle action potential (CMAP)	48 months from baseline
PAMC area: mV / ms	Compound muscle action potential (CMAP)	48 months from baseline
Maximum force developed in an isometric contraction of the muscles	The measurement will be made with a dynamometer during dorsiflexion of the foot (from certain angles) and during abduction of the index finger of the hand, respectively.	48 months from baseline
Fuerza muscular (MRC Medical Research Council) score	Muscle strength data will be collected according to the Medical Research Council scale. Muscle strength is graded on a scale of 0 to 5, with 5 being normal muscle strength and 0 being the absence of muscle contraction.	48 months from baseline

Collaborators and Investigators

• Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

Study record dates

Study Major Dates

• Study Start (Anticipated): May 1, 2021
• Primary Completion (Anticipated): May 1, 2023
• Study Completion (Anticipated): September 1, 2023

Study Registration Dates

• First Submitted: April 15, 2021
• First Submitted That Met QC Criteria: April 15, 2021
• First Posted (Actual): April 19, 2021

Study Record Updates

• Last Update Posted (Actual): April 19, 2021
• Last Update Submitted That Met QC Criteria: April 15, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuromuscular Diseases; Neurodegenerative Diseases; Spinal Cord Diseases; TDP-43 Proteinopathies; Proteostasis Deficiencies; Sclerosis; Motor Neuron Disease; Amyotrophic Lateral Sclerosis
• Other Study ID Numbers: IMB-TCIM/ELAII-2019-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No